Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals

Arielle J. Labiner, Anne Aronson, Aimee L. Lucas

Research output: Contribution to journalReview articlepeer-review


Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with high mortality, largely due to late stage at diagnosis. Approximately 10% to 15% are hereditary, and detection of early stage PDAC or precursor lesions through pancreatic surveillance programs may improve outcomes. Current surveillance is annual, typically with endoscopic ultrasound and/or magnetic resonance imaging.

Original languageEnglish
Pages (from-to)929-942
Number of pages14
JournalHematology/Oncology Clinics of North America
Issue number5
StatePublished - Oct 2022


  • Cancer screening
  • Consensus guidelines
  • Familial pancreatic cancer
  • High-risk
  • Pancreatic ductal adenocarcinoma
  • Pancreatic surveillance


Dive into the research topics of 'Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals'. Together they form a unique fingerprint.

Cite this